Market openNon-fractional
89bio, Inc/ETNB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About 89bio, Inc
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Ticker
ETNB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Francisco, United States
Employees
70
Website
www.89bio.com
89bio, Inc Metrics
BasicAdvanced
$736M
Market cap
-
P/E ratio
-$2.02
EPS
1.03
Beta
-
Dividend rate
Price and volume
Market cap
$736M
Beta
1.03
Financial strength
Current ratio
15.031
Quick ratio
14.704
Long term debt to equity
4.839
Total debt to equity
5.347
Interest coverage (TTM)
-50.24%
Management effectiveness
Return on assets (TTM)
-20.99%
Return on equity (TTM)
-34.51%
Valuation
Price to book
1.4
Price to tangible book (TTM)
1.4
Price to free cash flow (TTM)
-4.41
Growth
Earnings per share change (TTM)
-17.63%
3-year earnings per share growth
-12.84%
What the Analysts think about 89bio, Inc
Analyst Ratings
Majority rating from 10 analysts.
89bio, Inc Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$52M
28.36%
Profit margin
0.00%
NaN%
89bio, Inc Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.52
-$0.45
-$0.50
-$0.54
-
Expected
-$0.41
-$0.53
-$0.50
-$0.46
-$0.57
Surprise
26.39%
-15.09%
1.01%
17.07%
-
89bio, Inc News
AllArticlesVideos
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
Seeking Alpha·1 month ago
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for 89bio, Inc stock?
89bio, Inc (ETNB) has a market cap of $736M as of July 05, 2024.
What is the P/E ratio for 89bio, Inc stock?
The price to earnings (P/E) ratio for 89bio, Inc (ETNB) stock is 0 as of July 05, 2024.
Does 89bio, Inc stock pay dividends?
No, 89bio, Inc (ETNB) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next 89bio, Inc dividend payment date?
89bio, Inc (ETNB) stock does not pay dividends to its shareholders.
What is the beta indicator for 89bio, Inc?
89bio, Inc (ETNB) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell 89bio, Inc stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.